drugset / Trial / NCT05252572
Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies
NaSingle-groupOpen-labelTreatment
Summary
Clinical Study on the Safety and Effectiveness of CLL1 CAR-T Cells in the Treatment of CLL1-positive Hematological Malignancies
Timeline
- Start
- 2022-02-28
- Primary completion
- 2024-11-30
- Completion
- 2024-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CLL1 CAR T-cells | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | CLL1 CAR T-cells | Cell therapy | 8e+06 cells/kg | Intravenous |